These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36033123)

  • 1. A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis.
    Langley PC
    Innov Pharm; 2021; 12(4):. PubMed ID: 36033123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.
    Langley PC
    Innov Pharm; 2023; 14(1):. PubMed ID: 38035319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).
    Langley PC
    Innov Pharm; 2020; 11(3):. PubMed ID: 34007634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
    Pane C; Di Stefano V; Cuomo N; Sarnataro A; Vinciguerra C; Bevilacqua L; Brighina F; Rini N; Puorro G; Marsili A; Garibaldi M; Fionda L; Saccà F
    J Neurol; 2024 Sep; 271(9):6209-6219. PubMed ID: 39080054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
    Langley PC
    Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis.
    Langley PC
    Innov Pharm; 2021; 12(4):. PubMed ID: 36033108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.
    Langley PC
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma.
    Langley PC
    Innov Pharm; 2022; 13(2):. PubMed ID: 36654713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease.
    Langley PC
    Innov Pharm; 2020; 11(2):. PubMed ID: 34007618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review.
    Langley PC
    Innov Pharm; 2021; 12(3):. PubMed ID: 35601587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.
    Langley PC
    Innov Pharm; 2020; 11(4):. PubMed ID: 34007652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nothing to Cheer About: Endorsing  Imaginary Economic Evaluations and Value Claims with CHEERS 22.
    Langley P
    F1000Res; 2022; 11():248. PubMed ID: 35444797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab improves fatigue in refractory generalized myasthenia gravis.
    Andersen H; Mantegazza R; Wang JJ; O'Brien F; Patra K; Howard JF;
    Qual Life Res; 2019 Aug; 28(8):2247-2254. PubMed ID: 30905021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facilitating bias in cost-effectiveness analysis: CHEERS 2022 and the creation of assumption-driven imaginary value claims in health technology assessment.
    Langley P
    F1000Res; 2022; 11():993. PubMed ID: 36226039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure.
    Langley PC; McKenna SP
    Innov Pharm; 2021; 12(2):. PubMed ID: 34345508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis.
    Barnett C; Bril V; Bayoumi AM
    Eur J Neurol; 2019 Mar; 26(3):452-459. PubMed ID: 30315714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.